P731 Stock Overview Operates as a pharmaceutical company in Canada and the United States. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Medexus Pharmaceuticals Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Medexus Pharmaceuticals Historical stock prices Current Share Price CA$2.56 52 Week High CA$3.14 52 Week Low CA$0.98 Beta 1.85 1 Month Change 42.22% 3 Month Change 62.03% 1 Year Change 54.22% 3 Year Change 38.38% 5 Year Change 4.92% Change since IPO -11.11%
Recent News & Updates
Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in Canada Nov 21
Second quarter 2025 earnings released: EPS: US$0.004 (vs US$0.053 loss in 2Q 2024) Nov 09
Investor sentiment deteriorates as stock falls 15% Nov 06
Medexus Pharmaceuticals Inc. to Report Q2, 2025 Results on Nov 07, 2024 Oct 30
First quarter 2025 earnings released: EPS: US$0.08 (vs US$0.032 in 1Q 2024) Aug 09
Medexus Pharmaceuticals Inc. to Report Q1, 2025 Results on Aug 07, 2024 Jul 31 See more updates
Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in Canada Nov 21
Second quarter 2025 earnings released: EPS: US$0.004 (vs US$0.053 loss in 2Q 2024) Nov 09
Investor sentiment deteriorates as stock falls 15% Nov 06
Medexus Pharmaceuticals Inc. to Report Q2, 2025 Results on Nov 07, 2024 Oct 30
First quarter 2025 earnings released: EPS: US$0.08 (vs US$0.032 in 1Q 2024) Aug 09
Medexus Pharmaceuticals Inc. to Report Q1, 2025 Results on Aug 07, 2024 Jul 31
Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 19, 2024 Jul 16
Full year 2024 earnings released: US$0.01 loss per share (vs US$0.061 profit in FY 2023) Jun 26
Medexus Pharmaceuticals Inc. to Report Q4, 2024 Results on Jun 25, 2024 Jun 19
Medexus Pharmaceuticals Inc. Announces FDA Accepts for Review Treosulfan NDA Jun 08
Investor sentiment improves as stock rises 16% Apr 26
Investor sentiment improves as stock rises 16% Mar 28
Investor sentiment deteriorates as stock falls 33% Feb 14
Third quarter 2024 earnings released: US$0.022 loss per share (vs US$0.075 loss in 3Q 2023) Feb 08
Medexus Pharmaceuticals Inc. to Report Q3, 2024 Results on Feb 07, 2024 Jan 31
Medexus Pharmaceuticals Announces Health Canada Accepts for Review Medexus's New Drug Submission, or NDS, for Terbinafine Hydrochloride Nail Lacquer to Treat fungal N Infections Jan 09
Investor sentiment improves as stock rises 16% Jan 04
Investor sentiment improves as stock rises 30% Dec 20
Investor sentiment deteriorates as stock falls 16% Nov 16
Medexus Pharmaceuticals Inc. to Report Q2, 2024 Results on Nov 08, 2023 Nov 02
Investor sentiment deteriorates as stock falls 18% Oct 10 Medexus Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 10.000205 million. Oct 07
New minor risk - Shareholder dilution Oct 02
Investor sentiment improves as stock rises 17% Sep 11
Medexus Pharmaceuticals Announces the Presentation of Data from Phase 3/4 Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of IXINITY Aug 18
First quarter 2024 earnings released: EPS: US$0.032 (vs US$0.07 loss in 1Q 2023) Aug 10
Investor sentiment improves as stock rises 17% Aug 03
Medexus Pharmaceuticals Inc. to Report Q1, 2024 Results on Aug 09, 2023 Aug 03
New minor risk - Shareholder dilution Jul 25
Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 21, 2023 Jul 15
Independent Director recently bought €91k worth of stock Jul 03
New major risk - Share price stability Jun 30
Investor sentiment improves as stock rises 30% Jun 30
New major risk - Financial position Jun 22
Full year 2023 earnings released: EPS: US$0.06 (vs US$0.15 loss in FY 2022) Jun 22
Medexus Pharmaceuticals Inc. to Report Q4, 2023 Results on Jun 21, 2023 Jun 15 Medexus Pharmaceuticals Presents Positive New Data on Treosulfan That Researchers At Toronto's Princess Margaret Hospital Recently Presented At Mds 2023 Jun 14
Third quarter 2023 earnings released: US$0.075 loss per share (vs US$0.058 loss in 3Q 2022) Feb 09
Medexus Pharmaceuticals Inc. Announces Board Appointments Feb 07
Medexus Pharmaceuticals Inc. to Report Q3, 2023 Results on Feb 08, 2023 Feb 01
Medexus Pharmaceuticals Inc. Provides Earnings Guidance for the Third Quarter of 2023 Jan 13
Forecast breakeven date moved forward to 2024 Nov 17
Insufficient new directors Nov 16
Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.53 profit in 2Q 2022) Nov 10
Investor sentiment improved over the past week Nov 03
Medexus Pharmaceuticals Inc. to Report Q2, 2023 Results on Nov 08, 2022 Nov 03
Medexus Pharmaceuticals Inc. Provides Revenue Guidance for the Second Fiscal Quarter Ended September 30, 2022 Oct 07
Medexus Pharmaceuticals Provides Update on Treosulfan NDA Resubmission and Provides Business Update Sep 20
Investor sentiment deteriorated over the past week Sep 14
Investor sentiment improved over the past week Aug 15
First quarter 2023 earnings released: US$0.07 loss per share (vs US$0.34 loss in 1Q 2022) Aug 10
Medexus Pharmaceuticals Inc. to Report Q1, 2023 Results on Aug 08, 2022 Aug 03
Insufficient new directors Aug 01
Forecast breakeven date pushed back to 2025 Jul 27
Medexus Pharmaceuticals Inc. and Medac Resubmits New Drug Application for Treosulfan with the U.S. Food and Drug Administration Jul 26
Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 15, 2022 Jul 05
Insufficient new directors Jul 02
Full year 2022 earnings released: US$0.15 loss per share (vs US$1.86 loss in FY 2021) Jun 24
Medexus Pharmaceuticals Inc. to Report Q4, 2022 Results on Jun 22, 2022 Jun 15
Medexus Pharmaceuticals Announces American Journal of Hematology Has Accepted for Publication the Final Study Results Jun 07
Medexus Pharmaceuticals Provides Update on Resubmission of Treosulfan NDA May 26
Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Feb 11
Medexus Pharmaceuticals Inc. to Report Q3, 2022 Results on Feb 09, 2022 Feb 01
Medexus Pharmaceuticals Inc. Announces Clear Path to FDA Decision Following medac’s Type A Meeting with FDA on Treosulfan Dec 03
Second quarter 2022 earnings released: EPS US$0.53 (vs US$0.11 loss in 2Q 2021) Nov 14
Forecast to breakeven in 2024 Sep 23
Medexus Pharmaceuticals Inc. Announces Expanded Availability of Trecondyv® (Treosulfan) in Canada Sep 23
First quarter 2022 earnings released: US$0.34 loss per share (vs US$0.24 loss in 1Q 2021) Aug 18
Medexus Pharmaceuticals Inc. Completes Enrollment in Phase 4 Clinical Trial of IXINITY® Targeting Label Expansion for Pediatric Hemophilia B Patients Aug 13
Full year 2021 earnings released: US$1.86 loss per share (vs US$0.31 loss in FY 2020) Jun 19
Forecast breakeven pushed back to 2023 Jun 19
Medexus Pharmaceuticals Inc.(TSXV:MDP) dropped from S&P/TSX Venture Composite Index Jun 17
Medexus Strengthens Medical Affairs Team in Preparation for Planned Treosulfan Launch Jun 11
Medexus Pharmaceuticals Inc. Announces Availability of Triamcinolone Hexacetonide in the United States Jun 10
Third quarter 2021 earnings released: CA$1.18 loss per share (vs CA$0.19 loss in 3Q 2020) Mar 02
Revenue misses expectations Mar 02
Medexus Pharmaceuticals Inc. Announces Expanded Availability of Gleolan® in Canada Feb 26
Medexus Pharmaceuticals Inc. to Report Q3, 2021 Results on Mar 01, 2021 Feb 25
Medexus Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 28.286954 million. Feb 24
New 90-day high: €5.90 Feb 12
Medexus Announces Renewal and Expansion of Canadian Distribution Agreement for NYDA® Jan 26
New 90-day high: €4.74 Jan 22
New 90-day high: €4.46 Jan 05
Medexus Pharmaceuticals Inc. Enters into Exclusive License Agreement with Ethypharm Dec 20
New 90-day high: €3.56 Dec 04
Second quarter 2021 earnings released: CA$0.14 loss per share Nov 19
Revenue misses expectations Nov 19
Medexus Pharmaceuticals Inc. Reaches 50% Enrollment Target in Its Phase 4 Clinical Trial Investigating Ixinity® as Prophylactic Treatment for Pediatric Patients Under 12 Years of Age Nov 17
New 90-day high: €3.06 Nov 12
Medexus Pharmaceuticals Inc. to Report Q2, 2021 Results on Nov 16, 2020 Nov 10
New 90-day high: €2.86 Oct 16
Medexus Pharmaceuticals Inc. Appoints Michael Pine as Senior Vice President of Business Development and Strategy Sep 26
New 90-day high - €2.62 Aug 20
First quarter earnings released Aug 12
Medexus Pharmaceuticals Inc. to Report Q1, 2021 Results on Aug 11, 2020 Aug 06
New 90-day high - €2.60 Aug 03 Shareholder Returns P731 DE Pharmaceuticals DE Market 7D -13.5% 4.0% 3.0% 1Y 54.2% -12.8% 13.2%
See full shareholder returns
Return vs Market: P731 exceeded the German Market which returned 13.1% over the past year.
Price Volatility Is P731's price volatile compared to industry and market? P731 volatility P731 Average Weekly Movement 12.5% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: P731's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: P731's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Show more Medexus Pharmaceuticals Inc. Fundamentals Summary How do Medexus Pharmaceuticals's earnings and revenue compare to its market cap? P731 fundamental statistics Market cap €70.99m Earnings (TTM ) €2.20m Revenue (TTM ) €100.57m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) P731 income statement (TTM ) Revenue US$104.76m Cost of Revenue US$44.15m Gross Profit US$60.61m Other Expenses US$58.31m Earnings US$2.30m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 0.093 Gross Margin 57.85% Net Profit Margin 2.19% Debt/Equity Ratio 129.8%
How did P731 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/21 15:53 End of Day Share Price 2025/01/21 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Medexus Pharmaceuticals Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Scott Henry Alliance Global Partners David Martin Bloom Burton & Co. Tania Armstrong-Whitworth Canaccord Genuity
Show 10 more analysts 
